Advertisement

Chemoprevention of Superficial Bladder Cancer

  • Ronald Lieberman
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 106)

Abstract

The development, evaluation and approval of promising agents for bladder cancer prevention (chemoprevention) depends upon the rational integration of four key components:a) Agents (pharmaceuticals, biologics and nutrients);b) Biomarkers (intermediate endpoints that predict for clinical response and risk reduction;c) Cohorts (well defined high risk target populations d) Designs (efficient trial designs linked to the clinical phase of development). The promise of this overall strategy is the ability to conduct faster, smaller and more cost effective trials which incorporate validated surrogate endpoints rather than conventional clinical endpoints (cancer incidence, recurrence and survival). Current National Cancer Institute (NCI) phase III bladder cancer chemoprevention trials in progress are described. Since most patients with superficial (transitional cell) bladder cancer present with early disease (Ta, T1, Tis lesions) that frequently recurs and is easily accessible by serial cystoscopy and urine cytology, bladder cancer serves as a powerful clinical for conducting prevention trials of new agents for a tobacco related malignancy.

Keywords

Bladder Cancer Transitional Cell Carcinoma Surrogate Endpoint Bladder Cancer Risk Cancer Chemoprevention 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Greenlee, RT, Murray T, Bolden S and Wingo PA. Cancer statistics, 2000. CA- Cancer J Clin 2000; 50:7–33PubMedCrossRefGoogle Scholar
  2. 2.
    Parkin DM, Pisani P and Ferlay J. Global Cancer Statistics. CA Cancer J Clin 1999; 49:33–64PubMedCrossRefGoogle Scholar
  3. 3.
    Morgan JDT, Bowsher W, Griffiths DFR, Matthews PN. Rationalization of follow-up in patients with non-invasive bladder tumors. Br J Urol 1991; 67:158–161.PubMedCrossRefGoogle Scholar
  4. 4.
    Yu MC, Skipper PL, Taghizadeh K, Tannenbaum SR, Chan KK, Henderson BE. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels and bladder cancer risk in white, black and asian men in LosAngeles, California. J Natl Cancer Inst 1994; 86:712–716.PubMedCrossRefGoogle Scholar
  5. 5.
    van Poppel G, de Vogel N, van Balderen P, Kok F. Increased cytogenetic damage in smokers deficient in glutathione S-transferase isoenzyme mu. Carcinogenesis 1992; 13:303–305.PubMedCrossRefGoogle Scholar
  6. 6.
    Castelao JE, Yuan J-M, Gag-Dominguez M, Yu MC, Ross RK. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000; 82:1364–1369.PubMedCrossRefGoogle Scholar
  7. 7.
    Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Giovannucci EL. Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. J Natl Cancer Inst 1999; 91:605–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Giovannucci EL. N Engl J Med 1999; 340:1390–1397.PubMedCrossRefGoogle Scholar
  9. 9.
    Hopman AH, Moesher 0, Smeets AW et al. Numerical chromosome 1, 7, 9 and 11 alterations in bladder cancer detected by in situ hybridization. Cancer Res 1991; 51:646–651.Google Scholar
  10. 10.
    Tsai YC, Nichols PW, Hiti AL, et al. Allelic loss of chromosomes 9, 11 and 17 in human bladder cancer.Cancer Res 1990; 50:44–47.PubMedGoogle Scholar
  11. 11.
    Sidransky D, Frost P, von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med 1992; 320:737–740.CrossRefGoogle Scholar
  12. 12.
    Epstein H, Amin MB, Reuter VR, Mostofi FK, the Bladder Consensus Conference Committee. The world health organization/international society of urologic pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998; 22:1435–1438.Google Scholar
  13. 13.
    Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am. J. Surg Pathol 1999; 23:443–447.PubMedCrossRefGoogle Scholar
  14. 14.
    Lieberman R, Crowell JA, Hawk ET, Boone CW, Sigman C, Kelloff GJ. Development of new cancer chemoprevention agents:role of pharmacokinetic-pharmacodynamic and intermediate endpoint biomarker monitoring. Clin Chem 1998; 44:420–427.PubMedGoogle Scholar
  15. 15.
    Moon RC, Detrisac CJ, Thomas CF, Kelloff GJ. Chemoprevention of experimental bladder cancer. J Cell Biochem 1992; Supplement 161: 134–138.Google Scholar
  16. 16.
    Zhou J-R, Mukherjee P, Gugger ET, Tanaka T, Blackburn GL, Clinton SK. Inhibition of murine bladder tumorigenesis by soy isoflavones vial alteration in the cell cycle, apoptosis and angiogenesis. Cancer Res 1998; 58:5231–5238.PubMedGoogle Scholar
  17. 17.
    Jurincic CD, Engelmann U, Garsch J, Klippel KF. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J Urol 1988; 139:723–726.PubMedGoogle Scholar
  18. 18.
    Sarsody MF: A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract. Eur Urol 1997; Supplement: 20–26.Google Scholar
  19. 19.
    Lamm DL, Riggs DR, Shriver JS, van Gilder PF, Rach JF, De Haven IT. Megadose vitamins in bladder cancer: A double-blind clinical trial. J Urol 1994; 151:21–26.PubMedGoogle Scholar
  20. 20.
    Loprinzi CL and Messing EM. A prospective clinical trial of difluoromethylornithine (DFMO) in patients with resected superficial bladder cancer. J Cell Biochem 1992; Supplement 161:153–155.CrossRefGoogle Scholar
  21. 21.
    Sabichi AL, Lerner SP, Grossman HB, Lippman SM. Retinoids in the chemoprevention of bladder cancer. Current Opinion in Oncology 1998; 10:479–484.PubMedCrossRefGoogle Scholar
  22. 22.
    Koki AT, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Exp Opin Invest Drugs 1999; 8:1623–1638.CrossRefGoogle Scholar
  23. 23.
    Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KNM, Masferrer JL, Woerner BM, Snyder PW and Koki AT. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999; 59:5647–5650.Google Scholar
  24. 24.
    Grossman HB, Liebert M, Antelo M, Dinney CPN, Hu S-X, Palmer JL, Benedict W. p53 and RB expression predict progression in Ti bladder cancer. Clin Ca Res 1998; 4:829–834.Google Scholar
  25. 25.
    Kelloff GJ, Johnson JR, Crowell JA, Boone CW, DiGeorge J, Steele VE. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prey 1995; 4:1–10.Google Scholar
  26. 26.
    Wojcik EM, Miller MC, O’Dowd GJ, Veltri RW. Value of computer-assisted quantitative nuclear grading in differentiation of normal urothelial cells from low and high grade transitional cell carcinoma. Analyt Quant Cytol histol 1998; 20:69–76.Google Scholar
  27. 27.
    Ito H, Kyo S, Kanaya T, Takakura M, Koshida K, Namiki M, Inoue M. Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin Cancer Res 1998; 4:2807–2810.PubMedGoogle Scholar
  28. 28.
    Rao JY, Hemstreet GP, Hurst RE. “Molecular Pathology and Biomarkers of Bladder Cancer”. In Molecular Pathology of Early Cancer. S Srivastava, DE Henson and A Gazdar, eds. Amsterdam Netherlands. IOS Press, 1999.Google Scholar
  29. 29.
    Shenfeld J, Herr HW, Intervention strategies for chemoprevention of bladder cancer. J Cell Biochem 1992; Supplement 161:173–174.Google Scholar
  30. 30.
    Popp W, SchmiedengW, Speck M, et al. Incidence of bladder cancer in a cohort of workers exposed to 4-chloro-o-toluidine while synthesizing chlordimeform. Br. J. Indust Med 1992; 49:529Google Scholar
  31. 31.
    The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029–1035.Google Scholar
  32. 32.
    Anonymous. A catalog of cancer genes at the click of a mouse Science 1997; 276:1023–1024.CrossRefGoogle Scholar
  33. 33.
    Strausberg R, Dahl CA, Klausner RD. New opportunities for uncovering the molecular basis of cancer. Nat Genetics 1997; 15:415–416CrossRefGoogle Scholar
  34. 34.
    Backman V, Wallace MB, Perelman LT, Arendt JT, Gurjar R, Muller MG, Zhang Q, Zonios G, Kline E, McGillcan T, Shapshay S, Valdez T, Badizadegan K, Crawford JM, Fitzmaurice M, Kabani S, Levin HS, Seller M, Dasari RR, Itzkan I, Van Darn J, Feld M. Light scattering spectroscopy: A new technique for clinical diagnosis of precancerous and cancerous changes in human epithelia. Nature 2000; 406:35–36PubMedCrossRefGoogle Scholar
  35. 35.
    Mao L, Schoenberg MP, Scicchitano M, Erozan YS, Mario A, Schwab D, Sidransky D. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996; 271:659–662.PubMedCrossRefGoogle Scholar
  36. 36.
    Mao L, Lee JS, Fan YU, et al. Frequent microsatellite alterations at 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996; 2:682–685PubMedCrossRefGoogle Scholar
  37. 37.
    Lee JJ, Hong WK, Hindman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS.Papadimitrakopoulou VM, Geyer C, Perez C, Martin JW, El-Naggar AK, Lippman SM. Predicting cancer development in oral leukoplakia. Ten years of translational research. Clin Ca Res 2000; 6:1702–1710.Google Scholar
  38. 38.
    Spruck CH III, Ohneseit PF, Gonzalez-Zuletta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54:784–788.PubMedGoogle Scholar
  39. 39.
    Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res 1994; 54:531–538.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Ronald Lieberman

There are no affiliations available

Personalised recommendations